» Articles » PMID: 33098260

A Practical Approach to the Clinical Challenges in Initiation of Basal Insulin Therapy in People with Type 2 Diabetes

Overview
Specialty Endocrinology
Date 2020 Oct 24
PMID 33098260
Citations 10
Authors
Affiliations
Soon will be listed here.
Abstract

Initiating insulin therapy with a basal insulin analogue has become a standard of care in the treatment of type 2 diabetes mellitus (T2DM). Despite increasing choices in pharmacological approaches, intensified glucose monitoring and improvements in quality of care, many patients do not achieve the desired level of glycaemic control. Although insulin therapy, when optimized, can help patients reach their glycaemic goals, there are barriers to treatment initiation on both the side of the patient and provider. Providers experience barriers based on their perceptions of patients' capabilities and concerns. They may lack the confidence to solve the practical problems of insulin therapy and avoid decisions they perceive as risky for their patients. In this study, we review recommendations for basal insulin initiation, focussing on glycaemic targets, titration, monitoring, and combination therapy with non-insulin anti-hyperglycaemic medications. We provide practical advice on how to address some of the key problems encountered in everyday clinical practice and give recommendations where there are gaps in knowledge or guidelines. We also discuss common challenges faced by people with T2DM, such as weight gain and hypoglycaemia, and how providers can address and overcome them.

Citing Articles

Insulin therapy in type 2 diabetes: Insights into clinical efficacy, patient-reported outcomes, and adherence challenges.

Emad-Eldin M, Balata G, Elshorbagy E, Hamed M, Attia M World J Diabetes. 2024; 15(5):828-852.

PMID: 38766443 PMC: 11099362. DOI: 10.4239/wjd.v15.i5.828.


[Fixed ratio combinations GLP-1RA and basal insulin: literature review].

Kurkin D, Bakulin D, Morkovin E, Strygin A, Gorbunova J, Volotova E Probl Endokrinol (Mosk). 2024; 70(1):91-99.

PMID: 38433545 PMC: 10926250. DOI: 10.14341/probl13312.


The Barriers to Insulin Therapy Initiation in Type 2 Diabetes Patients: A Study of General Practitioner Perceptions in Huinan Community in South Shanghai.

Wen S, Ruan Y, Shi Z, Dan S, Zhou L Diabetes Metab Syndr Obes. 2024; 17:393-405.

PMID: 38283634 PMC: 10822111. DOI: 10.2147/DMSO.S446349.


Fixed-ratio Combinations (basal Insulin Plus GLP-1RA) In Type 2 Diabetes. an Analytical Review Of Pivotal Clinical Trials.

Vargas-Uricoechea H, Frias J, Vargas-Sierra H Rev Diabet Stud. 2023; 19(1):14-27.

PMID: 37185053 PMC: 10082333. DOI: 10.1900/RDS.2023.19.14.


Factors influencing insulin initiation in primary care facilities in Cape Town, South Africa.

Mathose T, Mash R S Afr Fam Pract (2004). 2023; 65(1):e1-e7.

PMID: 36861914 PMC: 9982463. DOI: 10.4102/safp.v65i1.5656.


References
1.
Tinahones F, Gross J, Onaca A, Cleall S, Rodriguez A . Insulin lispro low mixture twice daily versus basal insulin glargine once daily and prandial insulin lispro once daily in patients with type 2 diabetes requiring insulin intensification: a randomized phase IV trial. Diabetes Obes Metab. 2014; 16(10):963-70. PMC: 4237554. DOI: 10.1111/dom.12303. View

2.
Nystrom T, Bodegard J, Nathanson D, Thuresson M, Norhammar A, Eriksson J . Second line initiation of insulin compared with DPP-4 inhibitors after metformin monotherapy is associated with increased risk of all-cause mortality, cardiovascular events, and severe hypoglycemia. Diabetes Res Clin Pract. 2017; 123:199-208. DOI: 10.1016/j.diabres.2016.12.004. View

3.
Davis K, Tangirala M, Meyers J, Wei W . Real-world comparative outcomes of US type 2 diabetes patients initiating analog basal insulin therapy. Curr Med Res Opin. 2013; 29(9):1083-91. DOI: 10.1185/03007995.2013.811403. View

4.
Rodriguez-Gutierrez R, Gonzalez-Gonzalez J, Zuniga-Hernandez J, McCoy R . Benefits and harms of intensive glycemic control in patients with type 2 diabetes. BMJ. 2019; 367:l5887. DOI: 10.1136/bmj.l5887. View

5.
Bailey T, Grunberger G, Bode B, Handelsman Y, Hirsch I, Jovanovic L . AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY 2016 OUTPATIENT GLUCOSE MONITORING CONSENSUS STATEMENT. Endocr Pract. 2016; 22(2):231-61. DOI: 10.4158/EP151124.CS. View